A Phase I Safety Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy for the Treatment of Type 1 Diabetes

Trial Profile

A Phase I Safety Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy for the Treatment of Type 1 Diabetes

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs NBS 03 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Jul 2017 According to a Caladrius Biosciences media release, this study was published in Clinical Immunology.
    • 19 Jul 2017 According to a Caladrius Biosciences media release, two year results from this study were published in journal Translational Medicine.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top